Scientific Publications on PCA3

Following is a list of PCA3 and prostate-related literature and presentations, which we regularly update. You may access scientific papers abstracts or publications by clicking on the link, when available.

Scientific Papers

  1. de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, Gontero P, Mottaz A, Haese A., Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions, J Urol. 2011 Jun;185(6):2119-25. Epub 2011 Apr 15.
  2. Virginie Vlaeminck-Guillem, Marian Devonec, Marc Colombel, Claire Rodriguez-Lafrasse, Myriam Decaussin-Petrucci, Alain Ruffion, Urinary PCA3 Score Predicts Prostate Cancer Multifocality, DOI: 10.1016/j.juro.2010.11.072, February 21, 2011.
  3. Auprich M., Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budäus L, Fisch M, Huland H, Graefen M, Haese A, Critical assessment of preoperative urinary porstate cancer antigen 3 on the accuracy of prostate cancer staging, Eur Urol. 2011 Jan 59(1):96-105. Epub 2010 Oct 20.
  4. John R. Day (Gen-Probe inc.), Matthias Jost, Mark A. Reynolds, Jack Groskopf, Harry Rittenhouse, PCA3: From basic molecular science to the clinical lab, Elsevier Journal Cancer Letters, 2010 October 2010.
  5. Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol. 2010 Nov;184(5):1947-52.
  6. Perdonà S, Cavadas V, Di Lorenzo G, Damiano R, Chiappetta G, Del Prete P, Franco R, Azzarito G, Scala S, Arra C, De Sio M, Autorino R. Prostate Cancer Detection in the "Grey Area" of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3. Eur Urol. 2010 Oct 12.
  7. Ploussard, Guillaume, et al, Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients, BJU International, 2010 sept 30
  8. Roobol MJ, Schröder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, van Leeuwen PJ. Performance of Prostate Cancer Antigen 3 (PCA3) and Prostate-Specific Antigen in Prescreened Men: Reproducibility and Detection Characteristics for Prostate Cancer Patients with High PCA3 Scores (≥100). Eur Urol. 2010 Sep 26.
  9. Roobol MJ, Schröder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, Hessels D. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol. 2010 Oct;58(4):475-81. Epub 2010 Jul 9.
  10. Auprich M, et al, External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome, Eur Urol. 2010 Jul 3
  11. Jost M, Day JR, Slaughter R, Koreckij TD, Gonzales D, Kinnunen M, Groskopf J, Rittenhouse HG, Vessella RL, Reynolds MA. Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol Cancer. 2010 Jul 2;9:174.
  12. Remzi Mesut, et al, Follow up of men with an elevated pca3 score and a negative biopsy does an elevated pca3 score indeed predict the presence of prostate cancer ? BJU International, 2010 Mars 25
  13. Ploussard G, et al, The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int. 2010 Mar 10.
  14. R. S. Rittmaster, et al, Predictive value of PCA3 for prostate biopsy outcome in men receiving dutasteride: Results from the dutasteride REDUCE trial, 2010 Genitourinary Cancers Symposium (ASCO), March 2010
  15. J. Groskopf, et al, Validation of the PCA3 molecular urine test for predicting repeat prostate biopsy outcome in the placebo arm of the dutasteride REDUCE trial, 2010 Genitourinary Cancers Symposium (ASCO), March 2010
  16. Schilling D et al, The Prostate Cancer gene 3 assay: indications for use in clinical practice, BJU Int. 2009 Nov 20.
  17. David P. Wood, MD, IPF 2009 - Do we need new markers in prostate cancer? - Session Highlights, UroToday, October 22, 2009
  18. Cheryl Guttman et al, PCA3: Predictive performance superior to PSA, fPSA, Urology Times, Oct 1, 2009
  19. Scott B. Shapell, MD PHD, Leonard S. Marks, MD, Clinical use of urine PCA3 mRNA testing, Urology Times, Sep 1, 2009
  20. Daphne Hessels et al, The use of PCA3 in the diagnosis of prostate cancer, Nature Reviews Urology 6 , 255-261 (May 2009)
  21. Fradet, Yves, Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen, Current Opinion in Urology, 2009 May;19 (3):243-6
  22. Gerald L. Andriole, M.D. et al, Mortality Results from a Randomized Prostate-Cancer Screening Trial, The New England Journal of Medicine, Volume 360:1310-1319, March 26, 2009, Number 13
  23. Chunk FK et al, Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram, European Urology, 2009 Mar 13
  24. Kirby, R.S. et al, Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3), British Journal of Urology International (BJU Int), 2009 Feb;103(4):441-445
  25. Shappell, SB et al, PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting, J. Urol. 2009 Feb;73(2):363-8
  26. Whitman, E.J. et al, PCA3 Score Before Radical Prostatectomy Predicts Extracapsular Extension and Tumor Volume, The Journal of Urology, 2008 November; 180(5): 1975-1979
  27. Ankerst, D.P. et al, Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3, The Journal of Urology, 2008 October; 180(4): 1303-1308
  28. van Gils MP et al, Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results, The Prostate 2008 Aug 1;68(11):1215-22
  29. Marks LS et al, Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice, Reviews in Urology 2008 Summer;10(3):175-81
  30. Sokoll LJ, et al, A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy, Clinica Chimica Acta 2008; 389:1-6
  31. Haese, A. et al, Clinical utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy, European Urology (2008), doi: 10.1016/j.eururo.2008.06.071
  32. Nakanishi, H. et al, PCA3 Molecular Urine Assay Correlates With Prostate Cancer Tumor
    Volume: Implication in Selecting Candidates for Active Surveillance    , The Journal of Urology, 2008 May;179(5):1804-9
  33. Deras, IL et al., PCA3: a molecular urine assay for predicting prostate biopsy outcome, The Journal of Urology, 2008 Apr;179(4):1587-92
  34. Shappell, S.B., Clinical Utility of Prostate Carcinoma MolecularDiagnostic Tests, Reviews in Urology, 2008;10(1):44-69
  35. Popa, Ion et al., Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization, Modern Pathology, 2007 Nov;20(11):1121-7
  36. Jonathan L Wright et al, Newer Potential Biomarkers in Prostate Cancer, Reviews Urology 2007 Fall; 9(4): 207–213
  37. De la Taille A., ProgensaTM PCA3 test for prostate cancer detection, Expert Rev Mol Diagn 2007;7:491-7
  38. van Gils MP et al, Molecular PCA3 diagnostics on prostatic fluid, The Prostate, Volume 67, Issue 8, 881-887
  39. Reynolds, MA et al, Molecular markers for prostate cancer, Cancer Lett. 2007 Apr 28;249(1):5-13
  40. Marks, L.S. et al., PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat Biopsy, Urology, 69(3): 532-535, March 2007
  41. Fradet, Y. et al, uPM3, A New Molecular Urine Test for the Detection of Prostate Cancer, Urology 64 (2): 311-316, August, 2004
  42. Tinzl, M. et al, DD3PCA3 RNA Analysis in Urine – A New Perspective for Detecting Prostate Cancer, European Urology, Vol. 46(2), pages 182-187, August 2004
  43. Schalken, JA et al, New Targets for Therapy in Prostate Cancer: Differential Display Code 3 (DD3PCA3), a Highly Prostate Cancer-Specific Gene, Urology, 62 (5 Suppl 1):34-43, November 2003
  44. Hessels, D. et al., DD3PCA3-Based Molecular Urine Analysis for the Diagnosis of Prostate Cancer, European Urology, Vol. 44(1), pages 8-16, July 2003
  45. Leff, DN, Front-Running DD3PCA3 Gene Faced Off PSA Test of Prostate Carcinoma in First-Shot Urology Clinic Line-Up, BioWorld Today, July 10, 2003
  46. deKok, J. et al, DD3PCA3, a Very Sensitive and Specific Marker to Detect Prostate Tumors, Cancer Research, vol. 62, pages 2695-2698, May 2002
  47. Bussemakers, M. et al, DD3: A New Prostate-Specific Gene, Highly Overexpressed in Prostate Cancer, Cancer Research, Vol. 59, pages 5975-5979, December 1999

Posters and Presentations

  1. Schalken, J., PCA3 Is a Novel Genetic Marker, EAU Congress News, p. 17, March 23, 2007
  2. Groskopf, J. et al., The PCA3 Score is Independent of Prostate Gland Volume, and can Synergize with other Patient Information for Predicting Biopsy Outcome, EAU, March 2007
  3. Haese, A. et al, The Value of the PCA3 Assay in Guiding Decision Which Men With a Negative Prostate Biopsy Need Immediate Repeat Biopsy: Preliminary European Data, EAU, March 2007
  4. Nakanishi, H. et al, The Relationship Between PCA3 Score and Tumor Volume in Prostatectomy Samples, EAU, March 2007
  5. Overmyer, M., New PCa Assay Aids Critical Diagnostic Decisions, Urology Times, July 2006
  6. Fradet, Y. et al, PCA3 Molecular Urine Test: Development of a Method to Aid in Prostate Cancer Diagnosis, AUA, May 2006
  7. Marks, L.S. et al, Specificity of the PCA3 Molecular Urine Test for Prostate Cancer, AUA, May 2006
  8. Fradet, Y. et al, Performance of the PCA3 Urine Test on Subjects with Previous Negative Prostate Biopsies, AUA, May 2006
  9. Groskopf, J. et al, PCA3 Molecular Urine Assay: Characterization of a Method to Aid in the Diagnosis of Prostate Cancer, AUA, May 2006
  10. Bostwick, DG, PCA3Plus™: The Next Generation Genetic Test for Prostate Cancer Risk, AUA, May 2006
  11. Têtu, B. et al, PCA3DD3 Gene Expression is a Marker of Prostate Cancer, USCAP February 2005